Comparative study of potential for bisphosphonates to damage gastric mucosa of rats

Digestive Diseases and Sciences

Volumn 43, Issue 5, 1998, Pages 1009-1015

  Peter, C P ^a   Kindt, M V ^a   Majka, J A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bisphosphonates; Gastric irritation

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; EROSIVE GASTRITIS; FEMALE; LAMINA PROPRIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PYLORUS; RAT; STOMACH EPITHELIUM; STOMACH EROSION; STOMACH FUNDUS; STOMACH MUCOSA LESION; STOMACH PARIETAL CELL; STOMACH ULCER;

ALENDRONATE; ANIMALS; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETIDRONIC ACID; FEMALE; GASTRIC MUCOSA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031947732     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018826600877     Document Type: Article

References (15)

1. Fleisch H: Bisphosphonates: History and experimental basis. Bone 8(suppl 1):23-28, 1987
2. Fleisch H: Bisphosphonates: Pharmacology and use in treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 42:919-944, 1991
3. Fleisch H: Bisphosphonates in bone disease - from the laboratory to the patient. New York, The Parthenon Group, 1997
4. Fleisch H: Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 29:55-62, 1997
5. Chestnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC: Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 29:144-152, 1995
6. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong V, Egan KS, O'Fallon WM, Riggs BL: Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 4:320-322, 1994
7. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tollotson S, Seleznick MJ, Pinkas H, Wang KK: Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021, 1996
8. Saunders RL: Appearance of a gastric ulcer during diphosphonate therapy in a women with CRST syndrome. South Med J 70:1327-1329, 1977
9. Scurr JH, Cutting P: Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases. Br Med J 288:828-829, 1984
10. Reginster JYL: Oral tiludronate: Pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone 13:351-354, 1992
11. Hannuniemi R, Lauren L, Puolijoki H: Clodronate: An effective agent for the treatment of increased bone resorption. Drugs Today 27:375-390, 1991
12. Peter CP, Handt LK, Smith SM: Esophageal irritation due to alendronate sodium tablets: Possible mechanisms. Dig Dis Sci 1997 (in press)
13. Nixon GA, Buchler EV, Neuman EA: Preliminary safety assessment of disodium etidronate as an additive to experimental oral hygiene products. Toxicol Appl Pharmacol 22:661-671, 1972
14. Blank AM, Ems BL, Gibson GW, Myers WR, Berman K, Phipps RJ, Smith PN: Nonclinical model to assess gastric effects of bisphosphonates. Dig Dis Sci 42:281-288, 1997
15. Wallace JL, McKnight W, Davies NM, Elliott SN: Alendronate, an osteoporosis drug, increases the incidence and severity of NSAID-induced ulcers in rabbits and rats. AGA Research Forum Abstract, 1997 p A325